Cellectar Biosciences (CLRB) announced the signing of a strategic supply agreement with NorthStar Medical Radioisotopes, LLC, for the procurement of NorthStar’s non-carrier added Ac-225. The Company’s CLR 121225 development program combines its proprietary Phospholipid Ether, PLE, delivery platform and actinium 225 for the treatment of solid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB: